CRMD's DefenCath is an FDA-approved catheter lock solution reducing CRBSIs in chronic hemodialysis patients. CRMD saw higher-than-expected outpatient dialysis utilization of DefenCath, likely lifting ...

CorMedix (CRMD) drew fresh attention after reporting robust Q1 2026 results, with DefenCath playing a central role in revenue ...

CorMedix’s CRMD lead drug, DefenCath (Taurolidine + Heparin), is currently its only marketed product that generates revenues for the company. The FDA approved CorMedix’s DefenCath in late 2023 as the ...

CorMedix's Q4 revenues likely to be driven by strong DefenCath sales uptake in outpatient dialysis settings. CRMD's Melinta acquisition expanded its portfolio, recording incremental sales from seven ...

CorMedix raised its second-quarter sales forecast on Monday after disclosing that its large dialysis organization (LDO) partner has started implementing DefenCath with a broader reach than previously ...

BERKELEY HEIGHTS, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...

CorMedix’s CRMD lead therapy, DefenCath (taurolidine + heparin), is currently the company’s majority revenue driver. The FDA approved DefenCath in late 2023 as the first and only antimicrobial ...

CorMedix Inc. (NASDAQ:CRMD) reported third-quarter earnings of $1.26 per share on Wednesday, beating the consensus of 63 cents. Sales reached $104.27 million, a jump from $11.5 million a year ago, ...

The majority of CorMedix’s CRMD revenues come from its lead product, DefenCath, which is approved as the first and only antimicrobial catheter lock solution in the United States. The product is ...

CorMedix’s CRMD lead product, DefenCath (taurolidine plus heparin), is the company’s primary source of revenues. DefenCath was approved in 2023 as the first and only antimicrobial catheter lock ...